Table 1.
SARS-CoV-2 infections and reinfections during follow-up.
| Months from 2nd Dose of the BNT162b2 Vaccine * | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1.5 | 3 | 7 | 9 | 13 | 16 | 19 | 26 | Total | |
| N. of participants | 268 | 258 | 256 | 255 | 238 | 224 | 203 | 216 | 166 | - |
| SARS-CoV-2 infections (%) | 37 (14) | 13 (5) | 1 (0.4) | 14 (5.4) | 8 (3.3) | 72 (32) | 54 (27) | 83 (38) | 63 (38) | 345 |
|
- | 13 (100) | 1 (100) | 7 (50) | 7 (87.5) | 24 (33) | 24 (44) | 51 (61) | 47 (75) | 174 (50) |
|
37 (100) | 0 | 0 | 7 (50) | 1 (12.5) | 48 (67) | 30 (56) | 32 (38.5) | 16 (25) | 171 (50) |
|
37 (100) | 13 (100) | 1 (100) | 11 (79) | 4 (50) | 51 (71) | 38 (70) | 39 (47) | 23 (36.5) | 217 (63) |
|
0 | 0 | 0 | 3 (21) | 4 (50) | 21 (29) | 16 (30) | 44 (53) | 40 (63.5) | 128 (37) |
* All participants received two doses of BNT162b2. A booster dose of mRNA-1273 was administered to 248 (93%) study participants immediately after the 9-month time point; the bivalent Omicron-adapted BNT162b2 vaccine was administered to 93 (35%) study participants between the 19-month and the 26-month time points (see text for additional details).